甲状腺激素撤药期间L-三碘甲状腺原氨酸的药代动力学
LT3达峰时间1.8±0.32小时,呈快分布相和慢消除相,半衰期分别为2.3±0.11小时和22.9±7.7小时,支持二室模型;模型预测低剂量LT3(0.07 mcg/kg每日两次)联合LT4可预测性升高血清T3而无不显著超参考范围的峰值。
要点
- LT3达峰时间约1.8小时,分布相半衰期约2.3小时,消除相半衰期约22.9小时。
- LT3药代动力学符合二室模型,消除仅来自采样室。
- 模型预测LT3 0.07 mcg/kg每日两次联合LT4可稳定升高T3且峰值不显著超参考范围。
核心结论
- LT3药代动力学可由二室模型良好描述,具有快速分布相和缓慢消除相。
- 该信息有助于设计维持血清T3稳定的LT3/LT4联合治疗方案。
研究设计与样本
- 开放标签药代动力学研究,纳入因滤泡源性甲状腺癌准备核医学诊疗而撤药的患者。
- LT3以1:3 mcg/mcg剂量比替代LT4,每日三次,至少30天。
主要发现
- LT3达峰时间为1.8±0.32小时。
- 线性消除呈两相:快分布相半衰期2.3±0.11小时,慢消除相半衰期22.9±7.7小时。
- 药代动力学建模预测低剂量LT3(0.07 mcg/kg每日两次)联合LT4可预测性升高血清T3,且峰值不显著超参考范围。
临床怎么用
- LT3替代LT4时可按1:3 mcg/mcg剂量比每日三次给药。
- 低剂量LT3(0.07 mcg/kg每日两次)联合LT4的方案可能有助于维持T3在参考范围内。
局限性
- 第二次药代动力学研究仅5例患者完成。
- 研究人群为无内源性甲状腺激素产生且未接受LT4治疗的患者,外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: L-triiodothyronine (LT3) is a substitute for levothyroxine (LT4) for thyroid cancer (TC) patients during the preparation for nuclear medicine procedures, and it is used in combination with LT4 in patients who do not respond to the standard treatment for hypothyroidism. This therapy is commonly done by using fixed doses, potentially resulting in supraphysiologic levels of triiodothyronine (T3). A good understanding of the LT3 pharmacokinetics (PK) is necessary to design combination treatment schemes that are able to maintain serum T3 levels within the reference range, but data on the PK of LT3 are conflicting. Here, we present a study designed to characterize the PK of LT3 in patients devoid of endogenous thyroid hormone production, and not receiving LT4 therapy. Methods: We performed an open-label, PK study in patients undergoing thyroid hormone withdrawal in preparation for nuclear medicine procedures for the evaluation and treatment of follicular-derived TC. LT3 was substituted for LT4 at a 1:3 mcg/mcg dosage ratio thrice daily for at least 30 days. PK of the last LT3 dose while at steady state and terminal elimination was assessed over 11 days. Thereafter, a PK study was performed following the nuclear medicine procedure in patients who volunteered for a second study. Results: Fourteen patients age 48.5 ± 16.0 years completed the last dose study and five completed the second PK study. PK analysis indicates a time to maximum serum concentration of 1.8 ± 0.32 hours and two distinct phases of linear elimination, with a fast distribution phase and slow elimination phases with half-lives of 2.3 ± 0.11 hours and 22.9 ± 7.7 hours, supporting a two-compartment model. PK modeling predicts that a twice-daily administration of low-dose LT3 (0.07 mcg/kg twice daily) in combination with LT4 can predictably increase the serum T3 concentration without significant peaks above the reference range. Conclusions: The PK of LT3 is well described by a two-compartment model that assumes elimination only from the sampling compartment, with a rapid distribution phase and a slow elimination phase. This information will contribute to design therapeutic strategies for LT3/LT4 combination therapies directed to maintain stable T3 serum levels.
引用
- Van Tassell B, Wohlford GF, Linderman JD, et al. Pharmacokinetics of L-Triiodothyronine in Patients Undergoing Thyroid Hormone Therapy Withdrawal. Thyroid. 2019. PMID: 31364488. doi:10.1089/thy.2019.0101
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。